This Article Full Text Full Text (PDF) All Versions of this Article: 106/5/556    most recent 01.CIR.0000023530.86718.B0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koyama, J. Articles by Falk, R. H. Search for Related Content PubMed PubMed Citation Articles by Koyama, J. Articles by Falk, R. H. Pubmed/NCBI databases Medline Plus Health Information Amyloidosis Cardiomyopathy Related Collections Other heart failure Echocardiography

(Circulation. 2002;106:556.)
© 2002 American Heart Association, Inc.

Clinical Investigation and Reports

Prognostic Significance of Ultrasound Myocardial Tissue Characterization in Patients With Cardiac Amyloidosis

From Boston Medical Center, Section of Cardiology, Boston, Mass.

Correspondence to Dr Rodney H. Falk, Boston Medical Center, Section of Cardiology, 88 E Newton St, Boston, MA 02118. E-mail rfalk{at}bu.edu

Background— Cycle-dependent variation of myocardial integrated backscatter (CV-IB) is an objective measurement that may detect myocardial abnormalities. However, no data exist about the prognostic value of CV-IB in primary cardiac amyloidosis.

Methods and Results— We prospectively examined 208 consecutive biopsy-proven patients with primary amyloidosis. The magnitude of CV-IB was analyzed at the interventricular septum and left ventricular (LV) posterior wall and its prognostic value was compared with standard Doppler measurements with to the Tei index (isovolumic contraction time plus isovolumic relaxation time divided by ejection time). One hundred thirty-three patients had cardiac involvement (mean LV thickness > 12 mm). Forty-one patients (20%) (32 cardiac deaths) died during a mean follow-up of period of 307±156 days. Univariate analysis showed that the CV-IB at the LV posterior wall was the best predictor of cardiac death (P<0.0001) and all-cause death (P< 0.0001). The Tei index did not identify patients at risk of death. Multivariate analysis showed that CV-IB at the LV posterior wall was the only independent predictor of both cardiac and overall deaths.

Conclusions— Among patients with cardiac amyloidosis, CV-IB at the LV posterior wall is a powerful predictor of clinical outcome and is superior to standard echocardiographic/Doppler flow indexes.

Key Words: amyloid • prognosis • echocardiography

This article has been cited by other articles:

				B. A. Austin, W.H. W. Tang, E. R. Rodriguez, C. Tan, S. D. Flamm, D. O. Taylor, R. C. Starling, and M. Y. Desai Delayed Hyper-Enhancement Magnetic Resonance Imaging Provides Incremental Diagnostic and Prognostic Utility in Suspected Cardiac Amyloidosis J. Am. Coll. Cardiol. Img., December 1, 2009; 2(12): 1369 - 1377. [Abstract] [Full Text] [PDF]

				A. V. Kristen, F.-U. Sack, S. O. Schonland, U. Hegenbart, B. M. Helmke, A. Koch, P. A. Schnabel, C. Rocken, S. Hardt, A. Remppis, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis Eur J Heart Fail, October 1, 2009; 11(10): 1014 - 1020. [Abstract] [Full Text] [PDF]

				C. R. Morris, J. H. Suh, W. Hagar, S. Larkin, D. A. Bland, M. H. Steinberg, E. P. Vichinsky, M. Shigenaga, B. Ames, F. A. Kuypers, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease Blood, January 1, 2008; 111(1): 402 - 410. [Abstract] [Full Text] [PDF]

				E. Agabiti-Rosei, M. L. Muiesan, and M. Salvetti Review: New approaches to the assessment of left ventricular hypertrophy Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 119 - 128. [Abstract] [PDF]

				M. Salvetti, M. L. Muiesan, A. Paini, C. Monteduro, B. Bonzi, G. Galbassini, E. Belotti, E. Movilli, G. Cancarini, and E. Agabiti-Rosei Myocardial Ultrasound Tissue Characterization in Patients with Chronic Renal Failure J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1953 - 1958. [Abstract] [Full Text] [PDF]

				E Hyodo, T Hozumi, Y Takemoto, H Watanabe, T Muro, H Yamagishi, M Yoshiyama, K Takeuchi, and J Yoshikawa Early detection of cardiac involvement in patients with sarcoidosis by a non-invasive method with ultrasonic tissue characterisation Heart, November 1, 2004; 90(11): 1275 - 1280. [Abstract] [Full Text] [PDF]

				C J McMahon, S F Nagueh, R S Eapen, W J Dreyer, I Finkelshtyn, X Cao, B W Eidem, L I Bezold, S W Denfield, J A Towbin, et al. Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study Heart, August 1, 2004; 90(8): 908 - 915. [Abstract] [Full Text] [PDF]

				G. Palladini, C. Campana, C. Klersy, A. Balduini, G. Vadacca, V. Perfetti, S. Perlini, L. Obici, E. Ascari, G. M. d'Eril, et al. Serum N-Terminal Pro-Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis Circulation, May 20, 2003; 107(19): 2440 - 2445. [Abstract] [Full Text] [PDF]